Compare BridgeBio Pharma Inc (BBIO) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.48. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | EMLC | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $26.59 |
52-Week Low | $44.81 | $24.83 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
EMLC trades at $25.39, down 0.63% over 24 hours, with technical indicators signaling a bearish trend. The ETF maintains a consistent dividend payout, with recent distributions of $0.14 per share. News highlights focus on emerging market debt opportunities amid shifting global volatility, though short interest has risen significantly, indicating investor caution.
Outlook remains mixed; EMLC offers attractive yield above Treasuries but faces currency risk and capital erosion concerns. Key risks include Fed policy shifts and emerging market volatility. Institutional demand is growing, yet high short interest suggests skepticism about sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
